Past-Year Pap Testing Rates Were Lower in 2022 Than 2019

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

FRIDAY, June 14, 2024 -- Past-year Papanicolaou testing rates were lower in 2022 than in 2019, overall, and lower rates were seen in rural versus urban women, according to a study published in online June 14 in JAMA Network Open.

Tyrone F. Borders, Ph.D., and Amanda Thaxton Wiggins, Ph.D., from the University of Kentucky in Lexington, examined receipt of a Papanicolaou test in the past year among U.S. women overall and in those residing in rural and urban areas in 2019, 2020, and 2022. Data were obtained from the Health Information National Trends Survey; study participants were women aged 21 to 65 years.

Of the 188,243,531 women included in the analysis, 12.5 and 87.5 percent lived in rural and urban areas, respectively. The researchers found that unadjusted past-year Papanicolaou testing rates were significantly lower among rural versus urban residents in 2022 (48.6 versus 64.0 percent). Compared with 2019, in 2022 adjusted odds of past-year Papanicolaou testing were lower (odds ratio, 0.70).

"Health care organizations, especially those serving rural females, should consider, at least temporarily, expanding access to Papanicolaou tests to increase cervical cancer screening rates to prepandemic levels," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-06-15 07:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords